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Tracking Oxidatively Stressed Cardiac Stem Cells
With Molecular Imaging
“Insights” Into Fate, Viability, and Function*Sotirios Tsimikas, MDLa Jolla, CaliforniaRegenerationof cardiomyocytes,whichhavehistorically
been thought to be terminally differentiated, appears to
occur at a very slow, clinically nonsigniﬁcant rate. The
left ventricle has approximately 2 to 4 billion cells (1 g of
myocardiumhasw20million cardiomyocytes), and it is
estimated that normal aging results in loss of 1 g of
myocardium per year. Myocardial infarction and car-
diomyopathies are associated with substantial loss of
cardiomyocytes, which creates the strong clinical need
to accelerate any potential of cardiomyocyte regenera-
tion and recoup lost myocardial function (reviewed in
Laﬂamme and Murry [1]).See page 795Cardiac regenerative medicine has generated great
hope and enthusiasm in addressing unmet clinical
needs. Pluripotent progenitor cells, such as bone
marrow–derived mononuclear cells, mesenchymal
stem cells (MSCs), and cardiac-derived cells, have the
potential to allow recovery of myocardial function.
These beneﬁts of stem cells may occur through
transdifferentiation into mature functional cells, local
paracrine effects, or undeﬁned endogenous repair
mechanisms (2). Speciﬁcally, pluripotent stem cells
have the ability to differentiate into a variety of cells,
including cardiomyocytes, endothelial cells, vascular
smooth muscle cells, osteoblasts, chondrocytes, and
adipocytes. They can secrete a wide array of cytokines
that prevent ﬁbrosis and remodeling, induce neo-
vascularization, and stimulate proliferation of endoge-
nous cardiac stem cells into functional cardiomyocytes.*Editorials published in JACC: Cardiovascular Imaging reﬂect the views of
the authors and do not necessarily represent the views of JACC: Cardio-
vascular Imaging or the American College of Cardiology.
From the University of California San Diego, La Jolla, California.
Dr. Tsimikas is named as co-inventor and receives royalties on patents for
the commercial use of oxidation-speciﬁc antibodies held by the University
California.Against this background of initial optimism has
been the reality of the results of clinical trials,
using left ventricular myocardial contractile func-
tion as the primary endpoint and not clinical
endpoints, showing no change, transient beneﬁt, or
modest improvements (3). The reasons for these
disparate ﬁndings can be debated and include pa-
tient variables, extent of baseline left ventricular
dysfunction, choice of cell sources, preparation and
routes of delivery of progenitor cells, the hostile
milieu of the damaged myocardium affecting stem
cell survival, undeﬁned mechanisms of beneﬁt, and
chosen primary endpoints.
Although much has been done to optimize pro-
genitor cell characteristics in vitro, once injected,
there is uncertainty about how many of the cells
remain viable, engraft to the intended tissue, trans-
differentiate, and/or function as intended. The
consensus is that a low percentage of cells ultimately
engraft (4,5), which speaks to the lack of full un-
derstanding of the in vivo fate of the injected cells.
Therefore, tracking the fate, viability, and function
of progenitor stem cells seems to be a pre-requisite
to optimize their in vivo effectiveness, both at a
pre-clinical level for establishing a mechanistic un-
derstanding of their function, as well as at the
bedside in testing therapeutic hypotheses.
The paper by Psaltis et al. (6) in this issue of iJACC
provides insight into how stem cells are inﬂuenced by
their in vivo environment and points to a potential
method ofmonitoring stem cell viability and function.
They used the rationale that myocardial ischemia/
reperfusion (I/R) is associated with enhanced oxida-
tive stress and that rat MSCs exposed to hypoxia
upregulate pro-oxidant enzymes and have decreased
cell survival, a process ameliorated by hypoxic pre-
conditioning (7–9). In a series of well-designed
experiments, they developed a pathway-speciﬁc, re-
porter gene, molecular imaging approach to study rat
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804MSCs during I/R. They ﬁrst documented that the
pro-oxidant enzyme NAD(P)H oxidase p67phox was
upregulated in vitro in oxidatively stressed MSCs.
Then, they generated an oxidative stress sensor
composed of cell viability (CMV-Renilla luciferase)
and ﬁreﬂy luciferase (Fluc) reporter genes driven by
the NAD(P)H p67phox promoter. MSCs co-
transfected with NAD(P)H p67phox-Fluc were
transplanted transepicardially into a rat model of I/R
and imaged over 48 h using bioluminescence.
Compared to sham controls (no I/R) and corrected
for viable MSC number, cardiac Fluc intensity was
signiﬁcantly higher in I/R rats, indicating that they
were under increased cellular oxidative stress, either
endogenously or through exposure to oxidative stress
molecules derived from the infarcted and/or reper-
fused myocardium. Importantly for the speciﬁcity of
this pro-oxidant pathway, abrogation of oxidative
stress was documented whenMSCs were pre-treated
with tempol, a redox-cycling nitroxide that in-
activates many reactive oxygen species (ROS) and
improves nitric oxide bioavailability. Tempol has
been shown to preserve mitochondria against oxida-
tive damage and to protect a variety of organs,
including the heart, from I/R injury (10).
ROS are produced by almost all cell types, in
particular cells participating in acute and chronic
oxidative-inﬂammatory pathways, such as neutrophils
andmonocytes/macrophages (11). There are a variety
of mechanisms through which ROS are generated,
including nonenzymatic pathways through the res-
piratory chain of mitochondria and enzymatic path-
ways through speciﬁc enzymes. Important enzymes
include myeloperoxidase, which generates hypochlo-
rous acid; NADPH oxidases; and uncoupled endo-
thelial and inducible nitric oxide synthases, xanthine
oxidase, and cyclooxygenase, which generate a variety
of oxygen free radicals including superoxide anion,
nitric oxide, and hydrogen peroxide. These oxygen
free radicals are fairly weak oxidizing agents by
themselves, but in combination, such as when nitric
oxide reacts with superoxide to generate peroxynitrite,
very strong oxidizing agents are generated, with sig-
niﬁcant detrimental effects to cells and proteins.
I/R injury is associated with acute inﬂammatory
and pro-oxidant responses, particularly as oxygen-
rich blood perfuses through the ischemic and/or
infarcted endothelial cells and cardiomyocytes. The
generated ROS may injure cardiomyocytes, endo-
thelial cells, and engrafted stem cells (12). Injury to
cell and sarcolemmal membranes leads to calcium
overload, which in turn affects mitochondrial
membranes and triggers the processes of necrosis,
apoptosis, and organelle autophagy. It can alsogenerate oxidized sarcolemmal and mitochondrial
cell membranes and lead to the generation of
oxidized cholesteryl esters and oxidized phospho-
lipids (OxPL), which are known to have potent
pro-inﬂammatory and pro-apoptotic effects on
other cells (13,14). Inner mitochondrial membranes
are enriched in cardiolipin (w20% of the total lipid
composition, involved in optimal function of
mitochondrial energy metabolism) and other
phospholipids containing polyunsaturated fatty
acids that are highly amenable to lipid peroxidation
by ROS, in an analogous manner to the generation
of oxidation-speciﬁc epitopes on low-density lipo-
protein. The generated oxidized lipids, such as
OxPL, are highly bioactive and can mediate the
breakdown of cell junctions and stress ﬁbers, release
of pro-inﬂammatory cytokines such as interleukin-8
and monocyte chemotactic protein-1, quenching of
nitric oxide, and chemotaxis of pro-inﬂammatory
cells (13).
What are the positive attributes of this study? First, it
develops a paradigm for monitoring stem cell function
that may enhance our understanding of ultimate clin-
ical effectiveness. In this case, the function was upre-
gulation of pro-oxidant enzymes that were initiated by
the pro-oxidant environment of I/R. This approach,
however, may not be applicable in chronic heart failure
with depressed ejection fraction, in which acute
oxidative stress may be diminished. Second, it suggests
that oxidative stress is a pathway potentially leading to
poor long-term viability of stem cells. This naturally
suggests the possibility of using antioxidant therapies in
patients, in the injected stem cells or both, to mitigate
this process. These approaches can be tested in pre-
clinical models and include conventional antioxidants
or novel compounds such as antioxidant enzymes (15);
peptides; and oxidation-speciﬁc antibodies that have
high tissue uptake, can overcome the rapid kinetics of
generating ROS, and have prolonged therapeutic ef-
fects. Third, it suggests that molecular imaging may
play a signiﬁcant role in tracking the fate and deﬁning
the function and clinical viability of these pathways, at
least in pre-clinical models in which mechanistic data
can be more easily generated. This approach is analo-
gous to reporter gene imaging used in other pathways,
such as thymidine analogues 30-deoxy-30-[18F]ﬂuo-
rothymidine or 20-[18F]ﬂuoro-5-ethyl-1-beta-D-ara-
binofuranosyluracil (18F-FEAU) as positron emission
tomography (PET) tracers to identify viable, dividing
cells (16). Similar reporter gene functions can be
generated for other cellular pathways, such as moni-
toring DNA and protein synthetic activity to assess
replicative and regenerative capacity and relevant
cytokine release to quantitate paracrine function.
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805What are the limitations of this approach going
forward? First, transducing autologous cells ex vivo
with reporter genes and implanting them in pa-
tients is likely to face signiﬁcant regulatory hurdles
related to safety. Therefore, this approach may
have its initial applications in pre-clinical animal
models. Second, the imaging approach used here,
bioluminescence, although excellent for small ani-
mals, will have limited penetration and resolution
for imaging the heart in humans. Therefore, it can
be considered a proof-of-principle study until
modiﬁed to be used in more clinically translatable
imaging formats such as PET/computed tomog-
raphy or PET/magnetic resonance. Third, and
speciﬁcally related to the current approach of im-
aging increased oxidative stress, the biological and
pathophysiological implications of imaging oxida-
tive stress are not yet clearly deﬁned for stem cells.
Although pre-clinical studies suggest that oxidative
stress is detrimental to stem cell viability (8,9), this
has not been fully validated in vivo. For example,
do oxidatively stressed cells exhibit less regenera-
tive capacity, less engraftment and survival,
diminished release of beneﬁcial cytokines and
paracrine effects, and diminished biological activ-
ity? Furthermore, is NAD(P)H p67phox theoptimal measure of cellular oxidative stress?
Further study is required to understand the overall
role of enhanced oxidative stress on stem cell
viability and function.
As the ﬁeld of regenerative medicine evolves, in-
depth understanding of the underlying mechanisms
of their potential beneﬁt will be needed to tease out
those pathways best manipulated to attain the
greatest clinical beneﬁt. As these pathways are
discovered, molecular imaging is strongly poised to
stand side-by-side with scientiﬁc advancements in
knowledge of stem cells to provide a window into
their fate, viability, and function. By generating
novel and speciﬁc imaging probes that reﬂect well-
deﬁned pathophysiological pathways, as the inno-
vative work of Psaltis et al. (6) demonstrates, and
linking them with appropriate clinical imaging
modalities, novel “insights” may be obtained that
can accelerate the clinical translation of regenerative
medicine and ultimately lead to approved thera-
peutic modalities.
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